Please try another search
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurodegenerative diseases. Its products in the drug development stage includes PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce the disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.
Name | Age | Since | Title |
---|---|---|---|
John Alexander Moore | 57 | 2019 | Non-Executive Chairman |
Marcus Frampton | - | 2019 | Independent Non-Executive Director |
Jim Palmer | - | - | Member of Scientific Advisory Board |
Ian E. Dixon | - | 2020 | Non-Executive Director |
Rudiger Weseloh | - | 2019 | Independent Non-Executive Director |
Gilles Lambert | - | - | Member of Scientific Advisory Board |
Junichi Nabekura | - | - | Member of Scientific Advisory Board |
Christopher Todd Cox | 57 | 2019 | Non-Executive Director |
David Burke | - | - | Member of Scientific Advisory Board |
Gary Housley | - | - | Chairman of Scientific Advisory Board |
Gisela Mautner | - | 2022 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review